A novel K+ competitive acid blocker, YH4808, sustains inhibition of gastric acid secretion with a faster onset than esomeprazole: randomised clinical study in healthy volunteers.

@article{Yi2017ANK,
  title={A novel K+ competitive acid blocker, YH4808, sustains inhibition of gastric acid secretion with a faster onset than esomeprazole: randomised clinical study in healthy volunteers.},
  author={S Yi and Hyun Joo Lee and Seong Bok Jang and Hae Mi Byun and Seonghae Yoon and J-Y Cho and I-J Jang and K-S Yu},
  journal={Alimentary pharmacology & therapeutics},
  year={2017},
  volume={46 3},
  pages={337-346}
}
BACKGROUND YH4808, a K+ -competitive acid blocker, is under clinical development for the treatment of acid-related disorders, such as gastroesophageal reflux disease. AIMS To determine the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of YH4808, compared to placebo and esomeprazole. METHODS This double-blind, randomised, placebo- and active comparator (esomeprazole)-controlled study was conducted with 123 healthy male volunteers. We evaluated YH4808 (30-800 mg… CONTINUE READING
2 Citations
31 References
Similar Papers

Citations

Publications citing this paper.

References

Publications referenced by this paper.
Showing 1-10 of 31 references

Yh 4808 , a potent , highly selective K +competitive acid blocker , suppressed rat acute reflux esophagitis more effectively than esomeprazole

  • Oh S-W, J YoungSim, M HunCha
  • Gastroenterology
  • 2013

Similar Papers

Loading similar papers…